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BACKGROUND: Perﬂuoroalkyl substances (PFAS) may aﬀect body mass index (BMI) and other components of cardiometabolic (CM) risk during
childhood, but evidence is scarce and inconsistent.
OBJECTIVES:We estimated associations between prenatal PFAS exposures and outcomes relevant to cardiometabolic risk, including a composite CM-
risk score.
METHODS:We measured perﬂuorohexanesulfonic acid (PFHxS), perﬂuorooctanesulfonic acid (PFOS), perﬂuorooctanoic acid (PFOA), and perﬂuoro-
nonanoic acid (PFNA) in maternal plasma (ﬁrst trimester). We assessed weight gain from birth until 6 mo. At 4 and 7 y, we calculated the age- and
sex-speciﬁc z-scores for BMI, waist circumference (WC), and blood pressure (BP) (n  1,000). At age 4, we calculated the age-, sex-, and region-
speciﬁc z-scores for cholesterol, triglycerides (TGs), high-density (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (n=627). At age 4, we
calculated a CM-risk score (n=386) as the sum of the individual age-, sex-, and region-speciﬁc z-scores for WC, BP, HDL-C, and TGs. We used the
average between the negative of HDL-C z-score and TGs z-score to give similar weight to lipids and the other components in the score. A higher
score indicates a higher cardiometabolic risk at age 4.
RESULTS: PFOS and PFOA were the most abundant PFAS (geometric mean: 5.80 and 2:32 ng=mL, respectively). In general, prenatal PFAS concen-
trations were not associated with individual outcomes or the combined CM-risk score. Exceptions were positive associations between prenatal PFHxS
and TGs z-score [for a doubling of exposure, b=0:11; 95% conﬁdence interval (CI): 0.01, 0.21], and between PFNA and the CM-risk score
(b=0:60; 95% CI: 0.04, 1.16). There was not clear or consistent evidence of modiﬁcation by sex.
CONCLUSIONS:We observed little or no evidence of associations between low prenatal PFAS exposures and outcomes related to cardiometabolic risk
in a cohort of Spanish children followed from birth until 7 y. https://doi.org/10.1289/EHP1330
Introduction
Childhood obesity has been steadily increasing during the past
four decades (de Onis et al. 2010). Overweight children are more
likely to present obesity, hypertension, dyslipidemia, and cardio-
vascular disease in adulthood than normal-weight children
(Deshmukh-Taskar et al. 2006; Janssen et al. 2005). Obesity is
known to be caused by a mismatch between caloric intake and
energy expenditure, but early-life exposure to obesogens, includ-
ing perﬂuoroalkyl substances (PFAS), may play a role (Holtcamp
2012; La Merrill and Birnbaum 2012). PFAS are synthetic chem-
icals widely used in industrial and commercial applications,
including nonstick cookware, consumer products, textiles, and
food packaging (Buck et al. 2011; Casals-Casas and Desvergne
2011; Stahl et al. 2011). PFAS have been detected in cord blood
samples, suggesting that PFAS exposure starts prenatally (Inoue
et al. 2004; Manzano-Salgado et al. 2015).
Rodents prenatally exposed to perﬂuorooctanoic acid (PFOA)
showed higher weight gain, body fat accumulation, and cardi-
ovascular disease (Hines et al. 2009; Lv et al. 2013; Tan
et al. 2013). Epidemiological studies of the potential eﬀects of
PFAS on cardiometabolic outcomes in children have focused
primarily on the two most common PFAS, perﬂuorooctanesul-
fonic acid (PFOS) and PFOA (reviewed by Vrijheid et al.
2016). Prenatal exposure to PFOS and PFOA was associated
with lower weight at 5–12 mo of life (Andersen et al. 2010)
among >1,000 children from the Danish National Birth
Cohort (DNBC) study, but not with body mass index (BMI)
and waist circumference (WC) in a later follow-up of >800
children from the same cohort at age 7 (Andersen et al.
2013). Prenatal PFOS and/or PFOA exposure also was associ-
ated with higher weight at 20 mo in a study of 320 girls
from the Avon Longitudinal Study of Parents and Children
(ALSPAC) birth cohort (Maisonet et al. 2012), higher risk of
waist-to-height ratio (WHtR) >0:5 at 5–9 y in 1,022 children
from Greenland and Ukraine (Høyer et al. 2015), higher adi-
posity at 8 y in 204 American children (Braun et al. 2016),
and higher BMI among 345 Danish women, but not among
320 Danish men, at age 20 (Halldorsson et al. 2012). Prenatal
PFAS exposure was associated with higher BMI, skinfold
thickness, and total fat mass, measured using dual-energy X-
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ray absorptiometry (DXA) in 7-y-old girls (n=466), but not
boys (n=522) from a U.S. birth cohort (Mora et al. 2016).
However, estimated early-life PFOA exposure was not associ-
ated with self-reported BMI at 20–40 y among 8,764 adults
who resided near a PFOA manufacturing facility in the United
States (Barry et al. 2014).
In addition to overweight and adiposity, cardiometabolic risk
factors include elevated blood pressure (BP), lipid abnormalities,
and abnormal glucose homeostasis, all of which are considered
components of metabolic syndrome (Kassi et al. 2011). A cross-
sectional study of adolescent participants (12–19 y of age) in
the U.S. National Health and Nutrition Examination Survey
(NHANES) study reported inverse associations between perﬂuor-
ononanoic acid (PFNA) and metabolic syndrome, but positive
associations of PFOS with markers of abnormal glucose homeo-
stasis (Lin et al. 2009), while a second NHANES study reported
that PFOA and PFOS were inversely associated with hyperten-
sion in adolescents (Geiger et al. 2014b). Two additional cross-
sectional studies of PFOA and PFOS include a study of Danish
children at 8–10 y of age (n=342–499) that reported no associa-
tions with cardiometabolic risk factors in the population as a
whole (Timmermann et al. 2014), and a cross-sectional study of
>12,000 U.S. children and adolescents (1–18 y) with potential
exposure via contaminated drinking water, which reported posi-
tive associations with serum lipid levels (Frisbee et al. 2010).
Two longitudinal studies of PFAS and cardiometabolic risk fac-
tors, other than overweight and adiposity, include a study of girls
in the ALSPAC cohort, which reported that increasing prenatal
PFOA concentrations within the lowest tertile of the distribution
(but not in the second or third tertiles) was positively associated
with total cholesterol (TC) and low-density lipoprotein choles-
terol (LDL-C) at 7 and 15 y (111 and 88 girls, respectively)
(Maisonet et al. 2015). A U.S. study reported no association
between prenatal PFAS and insulin resistance at approximately 8
y of age (n=441), though concurrent serum PFOA and PFOS
were inversely associated with insulin resistance in a cross-
sectional analysis (n=541) (Fleisch et al. 2016).
In the present study, we evaluated prenatal exposures to four
PFAS in association with individual cardiometabolic risk factors
(anthropometric measurements, blood pressure, and serum lipids)
in early and midchildhood among participants in a Spanish birth
cohort. In addition, we estimated longitudinal associations with a
combined CM-risk score as an alternative predictor of overall
cardiometabolic risk (Eisenmann 2008; Pandit et al. 2011).
Methods
Study Population
We used data from the INMA (INfancia y Medio Ambiente,
Environment and Childhood) birth cohort study including three
Spanish regions: Gipuzkoa, Sabadell, and Valencia. A total of
2,150 pregnant women were recruited in the ﬁrst trimester of preg-
nancy [gestational age: median= 12:71 wk; interquartile range
ðIQRÞ=5:85] during the years 2003–2008. The inclusion criteria
were: 16 y old or older, intention of giving birth at the reference
hospital, singleton pregnancy, no language barrier, and no assisted
pregnancy (Guxens et al. 2012). Child anthropometric data at 6
mo was abstracted from medical records. Mother–child pairs were
then assessed when children were 4 and 7 y old. Maternal PFAS
concentrations were measured in serum samples from 1,243
women (58% of the initial cohort) who participated in follow-up
when their children were 4 y of age (Manzano-Salgado et al.
2016). The present analysis was limited to mother–child pairs with
prenatal PFAS concentrations and weight gain data for children at
6 mo (n=1,154), and with BMI at 4 y (n=1,230) and 7 y
(n=1,086) (Figure 1). In addition, WC and BP measurements
were available at 4 y of age for children from the Valencia and
Sabadell subcohorts (n=839, 68%); blood lipid levels were avail-
able for a subset of children from all three of the subcohorts
(n=627, 51%); and our derived CM-risk score, which was based
on WC, BP, high-density lipoprotein cholesterol (HDL-C), and
triglyceride (TG) (as described in detail below), was available for
386 children (31%) (Figure 1). All participating women signed
written informed consent. This study was approved by the re-
gional ethical committees of each cohort (Guxens et al. 2012).
Perfluoroalkyl Substances Determination
We collected maternal blood samples during the ﬁrst trimester
of pregnancy (median= 12:71 wk; IQR=5:85). Plasma was
aliquoted in 1:8 mL cryotube vials (Sigma-V7884, Nunc®
CryoTubes®) and stored at −80C until their analysis at the
Institute for Occupational Medicine, RWTH Aachen University
(Aachen, Germany), as previously described (Manzano-Salgado
et al. 2015). Brieﬂy, plasma concentrations of perﬂuorohexane-
sulfonic acid (PFHxS), PFOS, PFOA, and PFNA were deter-
mined by column-switching liquid chromatography (Agilent
1,100 Series high-performance liquid chromatography appara-
tus; Agilent Technologies) coupled with tandem mass spectrom-
etry (Sciex API 3,000 liquid chromatography coupled with
tandem mass spectrometry system in electrospray ionization-
negative mode; Applied Biosystems), according to a modiﬁed
protocol described by Kato et al. (2011). The limits of quan-
tiﬁcation (LOQ) and detection (determined as a signal-to-
noise ratio of 6 in the vicinity of the analytes) were
0:20 ng=mL and 0:10 ng=mL, respectively, for PFHxS, PFOS,
and PFOA, and 0:10 ng=mL and 0:05 ng=mL, respectively, for
PFNA (Manzano-Salgado et al. 2015).
Anthropometric Measurements
Assessment of anthropometric outcomes in INMA has been pre-
viously described (Valvi et al. 2013, 2015). Brieﬂy, we abstracted
height and weight measurements at birth and 6 mo from medical
registries, and calculated age- and sex-speciﬁc z-scores for
weight gain from birth to 6 mo using World Health Organization
(WHO) reference values (de Onis et al. 2009, 2007). Early rapid
Figure 1. Flow chart of sample populations in our study. Note: BP, blood
pressure; CM, cardiometabolic; Gip, Gipuzkoa; PFAS, perﬂuoroalkyl sub-
stances; Sab, Sabadell; Val, Valencia; WC, waist circumference.
Environmental Health Perspectives 097018-2
growth during the ﬁrst months of life has been associated with
later obesity (Monteiro and Victora 2005); therefore, we also
evaluated early rapid growth, deﬁned as a z-score >0:67 standard
deviation (SD) for weight gain from birth until 6 mo.
At 4 and 7 y, we measured weight (nearest 0:10 g) and height
(nearest 0:10 cm) using a standard protocol (with no shoes and in
light clothing) (Valvi et al. 2013). We calculated BMI (weight in
kg/height in cm2) and age- and sex-speciﬁc BMI z-scores using the
WHO reference (de Onis et al. 2009, 2007), and deﬁned overweight
as BMI z-score ≥85th percentile (de Onis et al. 2009, 2007). WC
was measured using an inelastic tape (SECA model 201; SECA) at
the midpoint between the right lower rib and the iliac crest, and after
a slight breath out. We derived age-, sex-, and region-speciﬁc WC
z-scores as the standardized residuals from a regression model of
WC as the dependent variable, and age, sex, and region as the pre-
dictors, following the method of Eisenmann (2008), with standardi-
zation by region used to account for diﬀerences among the three
regional subcohorts (Table S1) (Manzano-Salgado et al. 2016). We
used WC (cm) and height (cm) to calculate the WHtR, and deﬁned
high abdominal adiposity as WHtR> 0:5 based on previous studies
(Graves et al. 2014; Martin-Calvo et al. 2016; Mokha et al. 2010).
Blood Pressure
We used a digital automatic monitor (OMRON CPII) to measure
systolic and diastolic BP (SBP and DBP). At age 4 y, we did a sin-
gle measurement after ﬁve min of rest only, while at age 7 y, we
did two measurements (with an additional 5-min rest period in
between) and averaged the paired values for SBP and DBP, respec-
tively. We derived average BP at each age as the mean of the SBP
and DBP values. Similar to WC, we used regression models to derive
BP z-scores standardized by age, sex, height, and region (Sabadell
and Valencia at 4 y; Gipuzkoa, Sabadell, and Valencia at 7 y).
Lipids
In INMA, lipids were measured in all the children that agreed to
provide blood samples in the follow-up at 4 y (n=740). For the
purpose of the present study, we selected 627 children because
they also had matched maternal PFAS concentrations. Lipids
were measured using nonfasting blood samples (samples were
fasting for Valencia, but not for Sabadell or Gipuzkoa) collected
by venipuncture. We measured total TC, HDL-C, and TG levels
using standard analytical techniques (ABX-Pentra 400; Horiba
Medical). LDL-C was calculated based on TC, HDL-C, and TG
concentrations using the Friedewald formula (Fukuyama et al.
2008). As for WC, we derived age-, sex-, and region-speciﬁc
z-scores for TC and each individual lipid.
Cardiometabolic Risk Score
We derived a continuous CM-risk score at 4 y of age that is simi-
lar to the pediatric metabolic syndrome (MetS) score derived for
the IDEFICS study by Ahrens et al. (2014) for >16,000 children
at 2–9 y of age from eight European countries. Speciﬁcally, our
cardiometabolic (CM)-risk score was derived as the sum of the
standardized z-scores for WC, BP, and the mean of the HDL-C
and TG z-scores, with HDL-C multiplied by −1 because it is
inversely associated with cardiometabolic risk:
CM-risk score = WC z-scoreð Þ+ BP z-scoreð Þ
+
ð−HDL-C z-score +TGs z-scoreÞ
2
 
Our CM-risk score diﬀers from the Identiﬁcation and preven-
tion of dietary- and lifestyle-induced health eﬀects in children
and infants (IDEFICS) MetS score in that it does not include a
measure of glucose homeostasis; blood lipid levels were not
always measured in fasting blood samples; z-scores for individual
components were standardized by INMA study region (and by
height for BP), as well as by age and sex; and we used the aver-
age of SBP and DBP, rather than mean arterial pressure, to repre-
sent the BP component. A higher CM-risk score suggests higher
cardiometabolic risk.
Covariates
At enrollment (during the ﬁrst trimester of pregnancy), mothers
provided blood samples and completed self-reported question-
naires on sociodemographic and dietary factors, including the
maternal country of birth (Spain or other), region of residence
(Gipuzkoa, Sabadell, and Valencia), parity (0, 1, and ≥2), age (in
years), and weekly intakes of ﬁsh and seafood consumption dur-
ing the previous 3 mo of pregnancy (based on a food frequency
questionnaire) (Manzano-Salgado et al. 2016). In INMA, mothers
self-reported the duration of previous breastfeeding as the total
number of weeks for any previous pregnancy. Then we combined
all the durations into a single variable and classiﬁed their previ-
ous breastfeeding as none, <4mo, 4–6 mo, or >6mo. However,
in the present study, we used the continuous variable in the
models, that is, the total number of weeks of any previous breast-
feeding. Regarding prepregnancy BMI, in INMA, height was
measured, and prepregnancy weight was self-reported. Self-
reported prepregnancy weight and measured weight at 12 wk of
pregnancy were highly correlated; r=0:96; p<0:0001, (Casas
et al. 2013). We then used the reported prepregnancy weight and
measured height to calculate BMI (kg=m2), and classiﬁed moth-
ers as underweight, normal weight, overweight, and obese.
Further, the association between PFAS and fetal growth may be
confounded by maternal glomerular ﬁltration rate (GFR) during
pregnancy (Verner et al. 2015). Therefore, we also measured
maternal plasma creatinine (n=800) and calculated GFR
using the Cockcroft-Gault formula [GFR= ð140-maternal ageÞ×
weight ðkgÞ×1:04=serum creatinine ðlmol=LÞ]. Because plasma
albumin is the binding site of PFAS (D’eon et al. 2010), we
measured maternal albumin levels using the same maternal
plasma sample that was used for measuring PFAS concentrations
(n=800). Finally, in the follow-ups at the ages of 14 mo, 4 y,
and 7 y, mothers completed questionnaires with information on
postnatal characteristics of the index child, such as the duration
of breastfeeding (total number of weeks) and the level of physical
activity (Guxens et al. 2012).
Statistical Analysis
Since maternal PFAS concentrations were skewed to the right,
we transformed PFAS concentrations to a 2-base logarithm. For
PFAS with values under the LOQ (<4% for all compounds), we
used multiple imputations to assign a value between 0 and the
LOQ (0:20 ng=mL, and 0:10 ng=mL for PFNA) using the Stata
14.0 command ice. A detailed description of this procedure is
provided in Table S2. We used generalized additive models
(GAMs) of each log2–transformed PFAS and each outcome
(adjusted for maternal region of residence, country of birth, par-
ity, prepregnancy BMI, previous breastfeeding, and by the age at
follow-up and sex of the child) to assess potential departures
from linearity (p-value< 0:05). Based on this criterion, we found
evidence of nonlinearity for exposure–outcome relations at age 7
(data not shown), and therefore modeled associations with PFAS
concentrations categorized into quartiles, as well as associations
with log2 PFAS as continuous variables; otherwise, we modeled
continuous log2 PFAS concentrations only. We estimated
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associations between individual PFAS and each outcome using
multivariable linear regression models for continuous outcomes
(CM-risk score and z-scores for weight gain, BMI, WC, BP, TC,
HDL-C, LDL-C, and TG) and Poisson regression models for bi-
nary outcomes (rapid growth, overweight, and WHtR> 0:5).
Linear regression coeﬃcients represent the unit diﬀerence in each
outcome (where 1 unit is equivalent to a 1-SD diﬀerence in z-
scores, or a 1-unit diﬀerence in the CM-risk score) with a dou-
bling of prenatal PFAS concentration. Covariates included in the
model were selected based on our previous study of determinants
of PFAS concentrations in our cohort (Manzano-Salgado et al.
2016) and whether these determinants were associated with at
least one of the outcomes (p-value< 0:10). We further adjusted
all of our models by the age and sex of the child. Final models
were adjusted for maternal country of birth (Spain or other), parity
(number of pregnancies), previous breastfeeding (number of
weeks), age (years), prepregnancy BMI (kg=m2), and by the age
and sex of the child. We used multiple imputations to impute
missing covariate data (<5%) (Donders et al. 2006; Sterne et al.
2009), under the assumption that covariate data were missing at
random. We used Stata 14.0 command ice to create 20 diﬀerent
datasets for each age point (i.e., 6 mo, 4 y, and 7 y) and region of
residence (i.e. Gipuzkoa, Sabadell, and Valencia), and imputed
missing values as maternal and child characteristics (age, country
of birth, ﬁsh intake during pregnancy, education, etc.). A detailed
description of the imputation procedure is provided in Table S2.
Distributions of covariates in all the imputed datasets were similar
to those observed (see Table S3 for 4-y-old children from
Sabadell; otherwise, data not shown).
We performed various sensitivity analyses. Because PFAS
eﬀect may diﬀer by sex (Andersen et al. 2010; Halldorsson et al.
2012), we evaluated if the sex of the child modiﬁed our results by
including the interaction term in the models (i.e., considered
signiﬁcant if p-value for PFAS  sex-interaction< 0:05) and by
stratifying our analysis. Moreover, children with low birth weight
(LBW) (i.e., <2,500 g) or preterm (i.e., before 37 wk of gesta-
tion) might have a diﬀerent growth pattern than the rest of chil-
dren, so we repeated our analysis excluding children with LBW
(n=56) and born preterm (n=48). Further, we excluded children
born by cesarean section (n=210) because a higher risk of obe-
sity later in life has been suggested (Blustein et al. 2013). We
also introduced maternal GFR as a confounder to evaluate if it
changed our associations. Because albumin levels decrease dur-
ing pregnancy (Glynn et al. 2012; van den Akker et al. 2008), we
introduced albumin levels during pregnancy as a potential con-
founder in our models. Further, we stratiﬁed our models by
breastfeeding duration of the index child as a proxy of postnatal
PFAS exposure [never, short-term (<4mo), long-term (4–6 mo),
and very long-term (>6mo)]. Finally, as PFAS are correlated in
our cohort (Manzano-Salgado et al. 2015, 2016), we assessed
whether introducing all PFAS into a single model changed the
estimates for associations with CM-risk scores only.
We used the STATA 14.1 statistical software (Stata Corporation)
for our analysis. We considered a p-value< 0:05 to be statistically
signiﬁcant.
Results
Mothers included in our study were more likely to be older,
nulliparous, and with university studies compared to mothers
without PFAS measured (this comparison does not include
children who were excluded from analyses of lipids, BP, or
CM-risk score) (Table S4). Geometric mean concentrations of
PFAS ranged between 0:61 ng=mL for PFHxS and 5:80 ng=mL
for PFOS (Table 1). PFAS were moderately correlated, with
PFOA and PFNA (Spearman rho: 0.68 p-value< 0:001) being
the most correlated, and PFHxS and PFNA being the least cor-
related (Spearman rho: 0.43 p-value < 0:001). Twenty-four per-
cent of our children were classiﬁed as rapid growers at 6 mo,
and 27% and 34% were classiﬁed as overweight at 4 and 7 y,
respectively (Table 2). At 4 and 7 y, 26% and 19% of children
had high abdominal adiposity (i.e., WHtR> 0:5), respectively
(Table 2). Overall, the associations between PFAS and rapid
growth, overweight, and WHtR> 0:5 were close to the null
and not signiﬁcant at any age (see Table S5). In this study, we
describe the results from the adjusted models because we
consider that they are closer to the true association of PFAS
on cardiometabolic risk during childhood (for unadjusted
models, see Table S6). Because no major diﬀerences in the
magnitude or direction of the eﬀect estimates were observed
between the analyses using imputed data vs. complete cases
only (n≤ 1,100) (Table S7), we only present the results
based on imputed datasets. Diﬀerences in the CM-risk scores
were more pronounced, but we do not consider this will
aﬀect interpretation (Table S7).
We observed few associations between prenatal PFAS con-
centrations, anthropometric measurements, and BP at any age
(Table 3). Maternal PFOA concentrations were positively associ-
ated with weight gain z-scores at 6 mo in boys [for a doubling of
PFOA, b=0:13; 95% conﬁdence interval (CI): 0.01, 0.26] but not
girls (b= − 0:03; 95% CI: − 0:14, 0.08) (p-value for sex-
interaction= 0:28) (Table 3). PFHxS was negatively associated
with weight gain from birth to 6 mo in the overall population
(b= − 0:06; 95% CI: −0:15, 0.03) and in boys and girls, though
the association was not statistically signiﬁcant (Table 3). There
were no other signiﬁcant associations for the other PFAS at this
age (Table 3). At 4 and 7 y, we did not observe any statistically
signiﬁcant association between PFAS and anthropometric meas-
urements and BP (Table 3). However, we observed a pattern of
inverse associations between PFHxS, BMI, and WC z-scores in
the overall population and in boys (Table 3), whereas for girls,
positive associations were observed (p-value for sex-interaction at
4 y≥ 0:12 and at 7 y≥ 0:16). At these ages, PFOS, PFOA, and
PFNA showed patterns of positives associations with BMI
z-scores in the overall population and in boys (p-value for sex-
interaction> 0:18). Further, at 7 y, we observed nonsigniﬁcant
associations between PFOA and BP z-scores that were positive in
boys but negative in girls (p-value for sex-interaction= 0:11).
Finally, at age 7, we repeated the analysis using quartiles of PFAS
exposure (instead of the continued variable) because GAM mod-
els showed nonlinearity for exposure–outcome relations at this
age. Using quartiles of PFAS exposure yielded patterns of positive
associations, although not statically signiﬁcant, between PFOS,
WC, and BP z-scores, and PFNA, BMI, and WC z-scores at 7 y
(Figure S1). On the contrary, a pattern of inverse associations was
observed between PFOA and BP z-scores at 7 y (Figure S1).
As for the lipids measured at 4 y, we did not observe any stat-
istically signiﬁcant association between PFAS and z-scores of
TC, HDL-C, or LDL-C at 4 y. In general, associations between
Table 1. Perfluoroalkyl substance (PFAS) concentrations (ng/mL) in mater-
nal plasma during pregnancy.
Compound nð%Þ>LOD p5 p25 GM p75 p95
PFHxS 1,185 (96.3) 0.28 0.43 0.61 0.84 1.39
PFOS 1,230 (100) 2.54 4.52 5.80 7.84 11.40
PFOA 1,230 (100) 0.97 1.63 2.32 3.31 5.24
PFNA 1,222 (99.3) 0.30 0.50 0.66 0.90 1.49
Note: Concentrations are from the study population at 4 y (n=1,230). GM, geometric
mean; LOD, limit of detection; p5, 25, 75, 95, percentiles 5, 25, 75, and 95; PFHxS, per-
fluorohexanesulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic
acid; PFOS, perfluorooctanesulfonic acid.
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prenatal PFAS and blood lipids at 4 y were close to the null
(overall and when stratiﬁed by sex) (Table 3). One exception was
the association between PFHxS and TGs at age 4 y, which was
positive overall (b=0:11; 95% CI: 0.01, 0.21) and in boys
(b=0:16; 95% CI: 0.03, 0.30) and girls (b=0:07; 95% CI:
−0:08, 0.22) (p-value for sex-interaction= 0:85). In addition,
while the association between PFOA and HDL-C was close to
the null in the combined population (b= − 0:04; 95% CI:
−0:15, 0.08), it was positive for girls (b=0:12; 95% CI: −0:02,
0.27) and negative for boys (b= − 0:20; 95% CI: −0:37,
−0:03), with p-value for sex-interaction= 0:10 (Table 3).
Children with available CM-risk scores had lower BMI (mean
BMI: 16.05 vs. 16.26; p-value= 0:03) and TGs (mean TGs:
71.08 vs. 85:34 mg=dL; p-value<0:001), but higher HDL-C lev-
els (mean HDL-C: 54.96 vs. 46:05 mg=dL; p-value< 0:001) than
the full sample at 4 y (data not shown). Prenatal exposures to
PFOS, PFOA, and PFNA were positively associated with CM-
risk scores at 4 y in the overall population (Figure 2, Table 3),
with a signiﬁcant association for PFNA (b=0:60; 95% CI:
0.04, 1.16) that was similar in magnitude for boys and girls
(p-value for sex-interaction= 0:86). There were no signiﬁcant
diﬀerences in associations with CM-risk scores between boys
and girls, though associations with PFOA were on opposite sides
of the null (p-value for sex-interaction= 0:45).
Regarding the sensitivity analyses, the associations between
PFOA and BMI z-scores at 4 and 7 y increased with breastfeeding
duration of the index child, and these associations were statisti-
cally signiﬁcant in very long-term breastfeeding duration, i.e., at
4 y: b=0:14 (0.03, 0.26; p-value for breastfeeding-interaction=
0:09) and at 7 y: b=0:17 (0.02, 0.32; p-value for breastfeeding-
interaction= 0:01) (Figure S2). Associations with the CM-risk
score diﬀered when estimated using a model that included all
four PFAS (compared with estimates from single PFAS models),
with coeﬃcients suggesting a stronger positive association with
PFNA (b=0:85; 95% CI: 0.01, 1.69), a weaker positive associa-
tion with PFOS (b=0:11; 95% CI: −0:73, 0.95), and a stronger
negative association with PFHxS (b= − 0:36; 95% CI: − 1:05,
0.33), while the association with PFOA changed from positive to
negative (b= − 0:26; 95% CI: − 1:20, 0.68). However, the mutu-
ally adjusted estimates were imprecise, and, with the exception
of the association with PFNA, none were clearly diﬀerent from
the null. After including GFR in our models, all estimated associ-
ations remained close to null, but the association between PFHxS
and BMI z-scores at 4 y changed from negative to positive, and
the CIs were reduced for the associations between PFOS and
PFOA and BMI z-scores at 4 y (Table S8). Similar results were
observed after including maternal albumin levels in our models
(Table S9). Finally, estimates remained similar after excluding
cesarean section (Table S10), LBW, or preterm infants (data not
shown because few observations were excluded).
Discussion
In this study with low prenatal PFAS concentrations, we
observed little or no association with cardiometabolic risk com-
ponents from birth until 7 y. None of the PFAS were signiﬁcantly
associated with anthropometric measurements or BP at 4 or 7 y.
A doubling of prenatal PFHxS was associated with signiﬁcantly
higher TGs z-scores at 4 y of age, and prenatal PFNA was associ-
ated with a signiﬁcantly higher CM-risk score. We did not
observe any other statistically signiﬁcant associations between
PFAS concentrations and lipid z-scores or the CM-risk score in
the overall population, or when stratiﬁed by sex.
In our study, low exposure levels of PFAS were not signiﬁ-
cantly associated with weight gain, BMI, overweight, or WC at
any age. Other studies with similar exposure levels found that
prenatal PFOS and PFOA exposure was associated with
WHtR> 0:5 at 7 y (n=1,022) (Høyer et al. 2015), and PFAS
were also associated with higher BMI, WC, skinfold thickness,
and DXA total fat mass in girls aged 7 (n=1,006) (Mora et al.
2016). In the Health Outcomes and Measures of the Environment
Study (n=204) with PFOA exposure levels above the U.S. aver-
age (median: 5:3 ng=mL vs. 2:3 ng=mL), prenatal PFOA expo-
sure was associated with higher BMI, WC, and adiposity at 8 y
Table 2. Summary of child characteristics in our study.
Child characteristic
6 mo
n=1,154
4 y
n=1,230
7 y
n=1,086
Age (months or years) (mean± SD) 6:1± 0:1 4:4± 0:2 7:4± 0:5
Anthropometric measurements
Weight (kg) (mean±SD) 7:7± 0:9 18:1± 2:6 27:3± 5:7
Height (cm) (mean±SD) 67:0± 2:4 105:7± 4:5 125:2± 6:0
Weight gain z-score (mean± SD) 0:09± 1:0 — —
Rapid growth (yes) n (%)a 270 (24) — —
BMI (kg=m2) (mean±SD) 17:1± 1:4 16:2± 1:6 17:2± 2:6
BMI z-score (mean±SD) −0:9± 0:9 0:6± 1:0 0:8± 1:2
Overweight (yes) n (%) — 336 (27) 367 (34)
Waist circumference (cm) (mean±SD) (n=839 at 4 y) — 51:2± 4:2b 58:2± 6:6
Waist circumference z-score (n=839 at 4 y) (mean±SD) — −0:01± 0:95b −0:01± 1:0
Waist-to-height ratio >0:5 (yes) n (%) (n=839 at 4 y) — 219 (26)b 204 (19)b
BP, mmHg (mean±SD) (n=839 at 4 y)
Systolic BP — 102:5± 15:6b 107:3± 9:8
Diastolic BP — 66:0± 15:4b 63:5± 8:5
BP z-score — 0:01± 1:0b 0:00± 1:0
Lipids, mg/dL (mean± SD) (n=627)
Total cholesterol — 167:7± 26:6 —
HDL-C — 51:5± 12:1 —
LDL-C — 100:8± 22:0 —
Triglycerides — 76:6± 36:9 —
CM-risk score (mean±SD) (n=386)b,c — −0:84± 4:0 —
Note: —, no data; BMI, body mass index; BP, blood pressure; CM, cardiometabolic; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD,
standard deviation.
aRapid growth was defined as a weight gain z-score from birth until 6 mo >0:67 SD.
bOnly Sabadell and Valencia subcohorts have available data for this outcome.
cCM-risk score is the z-scores for WC, BP, and the mean of the HDL-C and TG z-scores, with HDL-C multiplied by − 1.
Environmental Health Perspectives 097018-5
T
ab
le
3.
A
dj
us
te
d
as
so
ci
at
io
ns
be
tw
ee
n
m
at
er
na
lp
er
fl
uo
ro
al
ky
ls
ub
st
an
ce
(P
FA
S)
co
nc
en
tr
at
io
ns
(l
og
2-
tr
an
sf
or
m
ed
,i
n
ng
/m
L
)
an
d
ca
rd
io
m
et
ab
ol
ic
co
m
po
ne
nt
s
du
ri
ng
ch
ild
ho
od
.
C
ar
di
om
et
ab
ol
ic
co
m
po
ne
nt
s
n
PF
H
xS
PF
O
S
PF
O
A
PF
N
A
b
(9
5%
C
I)
p-
V
al
ue
se
x
in
te
ra
ct
io
n
b
(9
5%
C
I)
p-
V
al
ue
se
x
in
te
ra
ct
io
n
b
(9
5%
C
I)
p-
V
al
ue
se
x
in
te
ra
ct
io
n
b
(9
5%
C
I)
p-
V
al
ue
se
x
in
te
ra
ct
io
n
Fr
om
bi
rt
h
un
til
6
m
o
W
ei
gh
tg
ai
n
z-
sc
or
e,
ov
er
al
l
1,
15
4
−
0:
06
(−
0:
15
,0
.0
2)
−
0:
02
(−
0:
11
,0
.0
7)
0.
04
(−
0:
04
,0
.1
2)
0.
01
(−
0:
07
,0
.0
9)
G
ir
ls
56
8
−
0:
09
(−
0:
20
,0
.0
2)
0.
93
−
0:
09
(−
0:
21
,0
.0
4)
0.
54
−
0:
03
(−
0:
14
,0
.0
8)
0.
28
0.
00
(−
0:
11
,0
.1
1)
0.
86
B
oy
s
58
6
−
0:
03
(−
0:
15
,0
.1
0)
0.
05
(−
0:
08
,0
.1
9)
0.
13
(0
.0
1,
0.
26
)
0.
04
(−
0:
09
,0
.1
7)
A
t4
y
B
M
I
z-
sc
or
e,
ov
er
al
l
1,
23
0
−
0:
02
(−
0:
10
,0
.0
7)
0.
04
(−
0:
05
,0
.1
3)
0.
04
(−
0:
04
,0
.1
3)
0.
05
(−
0:
03
,0
.1
3)
G
ir
ls
60
0
−
0:
02
(−
0:
13
,0
.0
8)
0.
70
0.
02
(−
0:
10
,0
.1
4)
0.
99
0.
00
(−
0:
11
,0
.1
0)
0.
31
0.
02
(−
0:
08
,0
.1
2)
0.
26
B
oy
s
63
0
−
0:
02
(−
0:
15
,0
.1
1)
0.
05
(−
0:
08
,0
.1
8)
0.
09
(−
0:
03
,0
.2
2)
0.
08
(−
0:
04
,0
.1
9)
W
C
z-
sc
or
eb
,o
ve
ra
ll
83
9
−
0:
04
(−
0:
14
,0
.0
5)
−
0:
03
(−
0:
13
,0
.0
7)
0.
00
(−
0:
09
,0
.1
0)
0.
02
(−
0:
07
,0
.1
0)
G
ir
ls
41
2
0.
03
(−
0:
10
,0
.1
6)
0.
12
−
0:
04
(−
0:
18
,0
.1
0)
0.
73
−
0:
03
(−
0:
16
,0
.1
0)
0.
78
0.
02
(−
0:
10
,0
.1
4)
0.
97
B
oy
s
42
7
−
0:
11
(−
0:
25
,0
.0
3)
−
0:
02
(−
0:
17
,0
.1
3)
0.
04
(−
0:
10
,0
.1
8)
0.
02
(−
0:
11
,0
.1
4)
B
P
z-
sc
or
eb
,o
ve
ra
ll
83
9
−
0:
01
(−
0:
10
,0
.0
9)
−
0:
05
(−
0:
15
,0
.0
6)
−
0:
06
(−
0:
16
,0
.0
4)
−
0:
01
(−
0:
10
,0
.0
8)
G
ir
ls
41
2
0.
10
(−
0:
09
,0
.1
8)
0.
60
−
0:
06
(−
0:
22
,0
.0
9)
0.
74
−
0:
04
(−
0:
18
,0
.1
0)
0.
99
0.
05
(−
0:
08
,0
.1
8)
0.
39
B
oy
s
42
7
−
0:
06
(−
0:
20
,0
.0
8)
−
0:
02
(−
0:
18
,0
.1
4)
−
0:
08
(−
0:
23
,0
.0
7)
−
0:
07
(−
0:
20
,0
.0
6)
L
ip
id
s
T
C
z-
sc
or
e,
ov
er
al
l
62
7
0.
02
(−
0:
09
,0
.1
2)
0.
02
(−
0:
10
,0
.1
5)
0.
02
(−
0:
10
,0
.1
5)
0.
00
(−
0:
11
,0
.1
2)
G
ir
ls
31
8
0.
04
(−
0:
12
,0
.2
0)
0.
96
0.
05
(−
0:
13
,0
.2
3)
0.
74
0.
09
(−
0:
08
,0
.2
6)
0.
53
0.
05
(−
0:
11
,0
.2
1)
0.
85
B
oy
s
30
9
−
0:
02
(−
0:
17
,0
.1
3)
0.
00
(−
0:
18
,0
.1
7)
−
0:
05
(−
0:
22
,0
.1
3)
−
0:
05
(−
0:
22
,0
.1
2)
H
D
L
-C
z-
sc
or
e,
ov
er
al
l
62
7
−
0:
01
(−
0:
11
,0
.1
0)
−
0:
03
(−
0:
14
,0
.0
9)
−
0:
04
(−
0:
15
,0
.0
8)
−
0:
03
(−
0:
14
,0
.0
8)
G
ir
ls
31
8
0.
04
(−
0:
10
,0
.1
9)
0.
97
−
0:
03
(−
0:
18
,0
.1
3)
0.
71
0.
12
(−
0:
02
,0
.2
7)
0.
10
0.
04
(−
0:
10
,0
.1
8)
0.
34
B
oy
s
30
9
−
0:
06
(−
0:
22
,0
.1
0)
−
0:
02
(−
0:
20
,0
.1
6)
−
0:
20
(−
0:
01
,
−
0:
03
)
−
0:
10
(−
0:
27
,0
.0
7)
L
D
L
-C
z-
sc
or
e,
ov
er
al
l
62
7
−
0:
01
(−
0:
12
,0
.0
9)
0.
02
(−
0:
10
,0
15
)
0.
03
(−
0:
08
,0
.1
5)
0.
01
(−
0:
10
,0
.1
2)
G
ir
ls
31
8
0.
00
(−
0:
15
,0
.1
5)
0.
94
0.
07
(−
0:
11
,0
.2
5)
0.
51
0.
04
(−
0:
12
,0
.2
1)
1.
00
0.
02
(−
0:
13
,0
.1
8)
0.
71
B
oy
s
30
9
−
0:
04
(−
0:
18
,0
.1
0)
−
0:
02
(−
0:
20
,0
.1
5)
0.
02
(−
0:
15
,0
.1
9)
−
0:
01
(−
0:
17
,0
.1
6)
T
ri
gl
yc
er
id
es
z-
sc
or
e,
ov
er
al
l
62
7
0.
11
(0
.0
1,
0.
21
)
0.
05
(−
0:
06
,0
.1
7)
0.
04
(−
0:
07
,0
.1
5)
0.
03
(−
0:
07
,0
.1
4)
G
ir
ls
31
8
0.
07
(−
0:
08
,0
.2
2)
0.
85
0.
01
(−
0:
17
,0
.1
9)
0.
80
−
0:
01
(−
0:
17
,0
.1
6)
0.
79
0.
05
(−
0:
11
,0
.2
0)
0.
68
B
oy
s
30
9
0.
16
(0
.0
3,
0.
30
)
0.
09
(−
0:
06
,0
.2
4)
0.
08
(−
0:
06
,0
.2
2)
0.
02
(−
0:
12
,0
.1
6)
C
M
-r
is
k
sc
or
eb
,c
ov
er
al
l
38
6
−
0:
09
(−
0:
64
,0
.4
5)
0.
28
(−
0:
33
,0
.8
9)
0.
27
(−
0:
35
,0
.8
9)
0.
60
(0
.0
4,
1.
16
)
G
ir
ls
19
7
−
0:
14
(−
0:
93
,0
.6
4)
0.
77
0.
10
(−
0:
73
,0
.9
3)
0.
73
−
0:
22
(−
1:
10
,0
.6
6)
0.
45
0.
50
(−
0:
27
,1
.2
7)
0.
86
B
oy
s
18
9
−
0:
09
(−
0:
86
,0
.6
8)
0.
47
(−
0:
44
,1
.3
7)
0.
72
(−
0:
17
,1
.6
2)
0.
70
(−
0:
13
,1
.5
4)
A
t7
y
B
M
I
z-
sc
or
e,
ov
er
al
l
1,
08
6
−
0:
04
(−
0:
14
,0
.0
6)
0.
03
(−
0:
08
,0
.1
4)
0.
03
(−
0:
08
,0
.1
3)
0.
06
(−
0:
04
,0
.1
6)
G
ir
ls
53
5
0.
02
(−
0:
10
,0
.1
4)
0.
44
0.
05
(−
0:
09
,0
.2
0)
0.
60
−
0:
01
(−
0:
13
,0
.1
2)
0.
48
0.
00
(−
0:
12
,0
.1
3)
0.
18
B
oy
s
55
1
−
0:
10
(−
0:
25
,0
.0
5)
0.
02
(−
0:
15
,0
.1
9)
0.
07
(−
0:
10
,0
.2
3)
0.
12
(−
0:
04
,0
.2
8)
W
C
z-
sc
or
e,
ov
er
al
l
1,
08
6
−
0:
04
(−
0:
12
,0
.0
4)
0.
00
(−
0:
09
,0
.0
9)
−
0:
02
(−
0:
11
,0
.0
6)
0.
02
(−
0:
07
,0
.1
0)
G
ir
ls
53
5
0.
04
(−
0:
07
,0
.1
5)
0.
16
0.
04
(−
0:
09
,0
.1
7)
0.
42
−
0:
05
(−
0:
16
,0
.0
7)
0.
49
−
0:
03
(−
0:
14
,0
.0
8)
0.
26
B
oy
s
55
1
−
0:
11
(−
0:
23
,0
.0
1)
−
0:
02
(−
0:
16
,0
.1
1)
0.
01
(−
0:
12
,0
.1
4)
0.
07
(−
0:
05
,0
.1
9)
B
P
z-
sc
or
e,
ov
er
al
l
1,
08
6
0.
04
(−
0:
04
,0
.1
3)
0.
06
(−
0:
04
,0
.1
5)
−
0:
02
(−
0:
11
,0
.0
7)
0.
00
(−
0:
08
,0
.0
9)
G
ir
ls
53
5
0.
07
(−
0:
06
,0
.1
9)
0.
99
0.
06
(−
0:
09
,0
.2
0)
0.
92
−
0:
08
(−
0:
21
,0
.0
4)
0.
11
0.
00
(−
0:
12
,0
.1
3)
0.
70
B
oy
s
55
1
0.
00
(−
0:
11
,0
.1
1)
0.
04
(−
0:
08
,0
.1
7)
0.
04
(−
0:
08
,0
.1
6)
−
0:
01
(−
0:
12
,0
.1
1)
N
ot
e:
C
oe
ff
ic
ie
nt
s
re
pr
es
en
tt
he
av
er
ag
e
di
ff
er
en
ce
in
th
e
ou
tc
om
e
w
ith
a
do
ub
lin
g
of
th
e
ex
po
su
re
.B
M
I,
bo
dy
m
as
s
in
de
x;
B
P,
bl
oo
d
pr
es
su
re
;C
I,
co
nf
id
en
ce
in
te
rv
al
;C
M
,c
ar
di
om
et
ab
ol
ic
;H
D
L
-C
,h
ig
h-
de
ns
ity
lip
op
ro
te
in
ch
ol
es
te
ro
l;
L
D
L
-
C
,l
ow
-d
en
si
ty
lip
op
ro
te
in
ch
ol
es
te
ro
l;
PF
H
xS
,p
er
fl
uo
ro
he
xa
ne
su
lf
on
ic
ac
id
;P
FN
A
,p
er
fl
uo
ro
no
na
no
ic
ac
id
;P
FO
A
,p
er
fl
uo
ro
oc
ta
no
ic
ac
id
;P
FO
S,
pe
rf
lu
or
oo
ct
an
es
ul
fo
ni
c
ac
id
;T
C
,t
ot
al
ch
ol
es
te
ro
l;
W
C
,w
ai
st
ci
rc
um
fe
re
nc
e.
a M
od
el
ad
ju
st
ed
by
:m
at
er
na
lc
ha
ra
ct
er
is
tic
s
(i
.e
.,
re
gi
on
of
re
si
de
nc
e,
co
un
tr
y
of
bi
rt
h,
pr
ev
io
us
br
ea
st
fe
ed
in
g,
ag
e,
an
d
pr
ep
re
gn
an
cy
B
M
I)
,a
nd
th
e
ag
e
an
d
se
x
of
th
e
ch
ild
.N
ot
e
th
at
se
x
of
th
e
ch
ild
w
as
no
ti
nc
lu
de
d
in
th
e
m
od
el
s
st
ra
tif
ie
d
by
se
x.
b O
nl
y
Sa
ba
de
ll
an
d
V
al
en
ci
a
su
bc
oh
or
ts
ha
ve
av
ai
la
bl
e
da
ta
fo
r
th
is
ou
tc
om
e.
c C
M
-r
is
k
sc
or
e
is
th
e
z-
sc
or
es
fo
r
W
C
,B
P,
an
d
th
e
m
ea
n
of
th
e
H
D
L
-C
an
d
T
G
z-
sc
or
es
,w
ith
H
D
L
-C
m
ul
tip
lie
d
by
−
1.
Environmental Health Perspectives 097018-6
(Braun et al. 2016). On the contrary, the DNBC, where PFOS ex-
posure levels (median: 33:18 ng=mL) are considerably higher
than ours, prenatal exposure to PFOS and PFOA was nonsigniﬁ-
cantly associated with self-reported lower BMI (n=811), over-
weight, and WC (n=804) at age 7 (Andersen et al. 2013).
Diﬀerences in the outcome measure might explain the conﬂicting
results in prospective studies, though there are many other causal
and noncausal factors that also might contribute to variation
among studies.
We did not ﬁnd clear or consistent evidence of diﬀerences in
associations between boys and girls. Prenatal PFOA exposure
was associated with higher weight gain from birth until 6 mo in
boys, but not girls, though the diﬀerence was not signiﬁcant
(p-value for sex-interaction= 0:28). The opposite pattern was
seen in DNBC, where prenatal PFOA exposure (median:
5:25 ng=mL) was associated with lower weight and BMI at 5 and
12 mo in boys, but not in girls (Andersen et al. 2010). Eﬀects
might diﬀer between the present study and the DNBC because
exposures were higher in the DNBC, though other causal and
noncausal explanations are also possible.
Early-life BP is predictive of cardiovascular health in adult
life (Bao et al. 1995). In our study, we did not observe any statis-
tically signiﬁcant association between PFAS concentrations and
BP at any age. In line with our results, cross-sectional data from
the United States (n=1,655) showed no association between
PFAS and hypertension in children 12–18 y old (Geiger et al.
2014b). In the present study, BP was measured twice at 7 y of
age and averaged as recommended (Pickering et al. 2005), but
was measured only once at 4 y of age, and only in children from
two of the three study regions. We used the average of SBP and
DBP as our BP outcome, consistent with the study of Ahrens
et al. (2014), though other studies have evaluated SBP and DBP
as separate outcomes, or have used mean arterial pressure
(Eisenmann 2008; Geiger et al. 2014b; Sardinha et al. 2016;
Shaﬁee et al. 2013).
Elevated TG levels during childhood have been associated
with metabolic syndrome later in life (Berenson et al. 1998;
Miller et al. 2011). TGs tend to accumulate in the liver, and
PFAS are known to activate peroxisome proliferator–activated
alpha receptor, which is a nuclear receptor that regulates lipid
homeostasis in the liver (Lau et al. 2007; Rosen et al. 2008).
In our study, higher prenatal PFHxS concentrations were asso-
ciated with higher TG levels at 4 y, with higher point estimate
for boys, but given the low precision of the estimates and
p-value for sex-interaction= 0:85, there is not clear evidence of
a stronger association in boys than in girls. Few studies have
assessed PFAS eﬀect on lipids during childhood and adoles-
cence, and even though they are of cross-sectional design, they
suggest that PFAS, especially PFOS and PFOA, alter the lipid
proﬁle in children (Frisbee et al. 2010; Geiger et al. 2014a; Lin
et al. 2009; Zeng et al. 2015). The study of Frisbee et al.
(2010) from the C8 project (n>12,000 children aged 1–18 y
old) only measured PFOS and PFOA, and observed positive
associations of both with TC and LDL-C, with PFOS also pos-
itively associated with HDL-C. The study of Geiger et al.
(2014a) from the NHANES (n=814 children aged 12–18 y
old) only evaluated PFOA and PFOS, and reported that PFOA
was positively associated with LDL-C>110 mg=dL and with
HDL-C<40 mg=dL (these were used as parameters of dyslipi-
demia), and PFOS was positively associated with LDL-C>
110 mg=dL only. The study from Lin et al. (2009), also from
NHANES (n=474 children aged 12–18 y old), assessed PFHxS,
PFOS, PFOA, and PFNA, and observed that PFNA negatively
associated with HDL-C. The study of Zeng et al. (2015) in 225
Taiwanese children (aged 12–15 y), measured eight PFAS, and
observed that PFOS and PFNA associated with TC, LDL-C, and
TGs. Also, in a prospective study, prenatal PFOA in the lowest
tertile was positively associated with LDL-C, but not with TC,
HDL-C, or TG in girls at 7 and 15 y old (Maisonet et al. 2015).
Our CM-risk score included three of four individual compo-
nents (e.g., anthropometric measurements, BP, and lipids) that
are typically used to deﬁne metabolic syndrome (Eisenmann
2008). In our study, we observed higher CM-risk scores with
higher PFOS, PFOA, and PFNA, but the association was only sig-
niﬁcant for PFNA. In contrast, Lin et al. (2009) reported that se-
rum PFHxS, PFOA, PFOS, and PFNA concentrations in
NHANES participants 12–19 y of age were inversely associated
with the prevalence of metabolic syndrome (based on ≥three of
the following conditions: high WC, high serum TG, low serum
HDL, elevated SBP or DBP, medication for hypertension, or ele-
vated fasting blood glucose or medication to reduce blood glu-
cose), with a signiﬁcant negative association for PFNA. However,
direct comparisons between our study and Lin et al. (2009) are not
possible given diﬀerences in the study design, population age, and
outcome. In a Danish birth cohort study, prenatal exposure to
PFOA was associated with overweight at 20 y in women, but not
men (Halldorsson et al. 2012). Future research should include a
prospective assessment of prenatal PFAS exposure and follow-up
beyond early and midchildhood, with evaluation of sex-speciﬁc
associations in larger populations.
Maternal excretion rates during pregnancy may inﬂuence the
associations between prenatal exposure to PFAS and weight of
the child (Verner et al. 2015). In our study, we adjusted our mod-
els by maternal GFR, showing that excretion rates are unlikely to
Figure 2. Adjusted associations between maternal PFAS concentrations
(log2–transformed, in ng/mL) and cardiometabolic risk score at 4 y.
Abbreviations: CI, conﬁdence interval; CM, cardiometabolic; PFHxS, per-
ﬂuorohexanesulfonic acid; PFOS, perﬂuorooctanesulfonic acid; PFOA, per-
ﬂuorooctanoic acid; PFNA, perﬂuorononanoic acid. Model adjusted by:
maternal characteristics (i.e., region of residence, country of birth, previous
breastfeeding, age, and prepregnancy BMI), and the age and sex of the child.
Only Sabadell and Valencia subcohorts have available data for this outcome.
CM-risk score is the z-scores for waist circumference (WC), blood pressure
(BP), and the mean of the high-density lipoprotein cholesterol (HDL-C), and
triglyceride (TG) z-scores, with HDL-C multiplied by − 1. Note: Coeﬃcients
represent the average diﬀerence in the outcome with a doubling of the expo-
sure. Upper values represent the p-values of the sex interaction term.
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have confounded the association between maternal PFAS con-
centration in plasma and childhood cardiometabolic outcomes. In
the Project Viva cohort (United States), Fleisch et al. (2016)
reported that after adjusment for GFR, their exposure–outcome
estimates did not change by more than 10%. In the same cohort,
Mora et al. (2016) reported that adjusting for GFR marginally
strenghtened the associations between prenatal PFAS exposure
and adiposity in midchildhood, suggesting some confounding by
GFR. Both in the Project Viva and in our cohort, maternal PFAS
concentrations were measured early in pregnancy when changes
in GFR might not have a big impact on PFAS concentrations
(Verner et al. 2015).
The main strengths of our study are its prospective design and
large sample size for analyses of BMI and weight gain, and the
ability to estimate associations between prenatal PFAS exposures
and outcomes that may contribute to future cardiometabolic risk,
including weight gain from birth to 6 mo; BMI, WC, and BP at 4
and 7 y of age; and blood lipids and a composite CM-risk score
(based on WC, BP, and lipids) at age 4. Nevertheless, some meth-
odological limitations should be considered. First, lipid levels
were measured using fasting samples in children from the
Valencia region, but nonfasting samples for children from
Sabadell and Gipuzkoa, which may inﬂuence lipid levels, espe-
cially TGs. In addition, lipid concentrations were measured in
only a subset of children (n=627) at 4 y of age. Second, our
CM-risk score does not include a marker of glucose homeostasis,
which is one of the components that is normally used to deﬁne
metabolic syndrome (Ahrens et al. 2014; Eisenmann 2008).
Therefore, our CM-risk score might not fully characterize the
potential impact of PFAS on the prevalence of metabolic syn-
drome at age 4 or the future risk of cardiometabolic disease.
Future follow-ups with available information on glucose homeo-
stasis or insulin resistance at later ages are recommended. Third,
we could only calculate the CM-risk score in 386 children that
were generally healthier than the rest, thus limiting the extrapola-
tion of our result to the full sample at 4 y (n=1,230). Fourth, we
observed a pattern of positive associations between PFOA and
BMI z-scores at ages 4 and 7 y with longer duration of breast-
feeding for the index child. This ﬁnding suggests that postnatal
PFAS exposure may play a role on childhood cardiometabolic
risk, as similarly seen in other studies (e.g., Domazet et al. 2016;
Zeng et al. 2015); however, we lack a direct measurement of
postnatal PFAS exposure in our cohort. Fifth, women included in
this study were more likely to be older, nulliparous, and with
higher education than those excluded from the analysis. Given
that older and nulliparous women tend to have higher PFAS lev-
els (Manzano-Salgado et al. 2016), we probably included women
and children with exposures that were higher than exposures in
the cohort as a whole. Sixth, we cannot rule out the possibility of
chance ﬁndings due to multiple comparisons in our study, or the
possibility of uncontrolled confounding or bias due to measure-
ment errors or missing data. Finally, in this study, small sample
sizes for some of our analyses resulted in unstable or imprecise
estimates of association, particularly for the CM-risk score, lip-
ids, WC, and BP at 4 y, and for estimates stratiﬁed by sex.
Conclusions
In this study population exposed to low levels of PFAS, we found
little evidence of an association between prenatal PFAS exposure
and cardiometabolic risk during childhood. Although concerns
have been raised about the potential for bias due to changes in
maternal GFR during pregnancy, we measured PFAS early in
pregnancy (before such changes are likely to be pronounced),
and adjusting for GFR in a sensitivity analysis had little eﬀect on
our ﬁndings. Moreover, we evaluated multiple outcomes that
may contribute to cardiometabolic risk, including anthropometric
measurements, BP, lipid levels, as well as a combined risk score.
Our ﬁndings are consistent with two previous prospective studies
that reported little or no evidence of associations between prena-
tal PFAS exposure and obesity during early and midchildhood
(Andersen et al. 2013; Mora et al. 2016). Future studies with
follow-ups beyond midchildhood and with measures of glucose
homeostasis are needed to further elucidate the eﬀect of prenatal
PFAS exposure on cardiometabolic risk.
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